A randomized controlled trial to evaluate the effect of influenza vaccination and probiotic supplementation on immune response and incidence of influenza-like illness in an elderly population in Indonesia
Sukamto Koesnoe, Nuning Masjkuri, Asri Adisasmita, Samsuridjal Djauzi, Cissy Kartasasmita, Julitasari Sundoro, Mardiati Nadjib, Mondastri Korib, Alisa Nurul Muthia, Virly Nanda Muzellina, Ummu Habibah, Saskia Aziza Nursyirwan, Kristoforus Hendra Djaya, Novilia Sjafri Bachtiar, Rini Mulia Sari, Sukamto Koesnoe, Nuning Masjkuri, Asri Adisasmita, Samsuridjal Djauzi, Cissy Kartasasmita, Julitasari Sundoro, Mardiati Nadjib, Mondastri Korib, Alisa Nurul Muthia, Virly Nanda Muzellina, Ummu Habibah, Saskia Aziza Nursyirwan, Kristoforus Hendra Djaya, Novilia Sjafri Bachtiar, Rini Mulia Sari
Abstract
Aim: To investigate the effect of influenza vaccination with or without probiotic supplementation on the immune response and incidence of influenza-like illness (ILI) in the elderly.
Methods: A randomized double-blind, placebo-controlled trial with a modified factorial design was conducted in 554 healthy elderly subjects aged 67 ± 5.6 (ranging from 60-90) years old in the Primary Health Care Center (Puskesmas area) of the Pulo Gadung District East Jakarta. Subjects received either a trivalent influenza vaccine or placebo at the start of the study, and a probiotic supplement (Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011) or a placebo for 6 months. Subjects were randomly assigned into four intervention groups: influenza vaccine and probiotics (n = 141), influenza vaccine and placebo (n = 136), placebo and probiotics (n = 140), and both placebo (n = 137). The primary outcome was ILI incidence within 6 months. The secondary outcomes were seroprotection and seroconversion rates at 1, 4, and 6 months after administering the interventions.
Results: This study showed that the trivalent influenza vaccine increased seroprotection (RR 3.6 [95%CI 2.92-4.47]; p<0.010) and seroconversion (RR 29.8 [95%CI 11.1-79.5]; p<0.010) rates 1 month after vaccination in elderly people while the probiotic supplement did not alter influenza antibody titers (p = 1.000 and p = 0.210). The relative ILI incidence risk was similar between vaccinated and non-vaccinated groups, as well as in the probiotic group compared to the non-probiotic group.
Conclusion: The tested trivalent influenza vaccine significantly induced seroprotection and seroconversion in the vaccinated subjects, while probiotics administration did not influence these parameters. Vaccinated individuals displayed a similarly low ILI incidence as those in the Control Group. However, the observed trend towards a reduction of ILI incidence with probiotics supplementation warrants further assessments in a larger, at-risk population.
Clinical trial registry number: NCT03695432.
Conflict of interest statement
The authors have read the journal’s policy and the authors of this manuscript have the following competing interests: NSB and RMS are paid employees of PT. Bio Farma whose product has been investigated in the study (the trivalent inactivated influenza vaccine). This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no other patents, products in development or marketing products to declare.
Figures
References
- Nichol K. L., Wuorenma J., & von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med.1998; 158(16): 1769–1776. doi: 10.1001/archinte.158.16.1769
- Stott D. J., Kerr G., & Carman W. F. Nosocomial transmission of influenza. Occup Med (Lond). 2002; 52(5): 249–253. doi: 10.1093/occmed/52.5.249
- Taubenberger J. K., & Layne S. P. Diagnosis of influenza virus: coming to grips with the molecular era. Mol Diagn. 2001; 6(4): 291–305. doi: 10.1054/modi.2001.28063
- Zambon M., Hays J., Webster A., Newman R., & Keene O. Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza. Arch Intern Med. 2001; 161(17): 2116–2122. doi: 10.1001/archinte.161.17.2116
- RI, B. P. d. P. K. K. K. (2013). Riset Kesehatan Dasar 2013.
- Glezen W. P., Greenberg S. B., Atmar R. L., Piedra P. A., & Couch R. B. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000; 283(4): 499–505. doi: 10.1001/jama.283.4.499
- Osterholm M. T., Kelley N. S., Sommer A., & Belongia E. A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12(1): 36–44. doi: 10.1016/S1473-3099(11)70295-X
- Hara M., Tanaka K., Kase T., Maeda A., & Hirota Y. Evaluation of seasonal influenza vaccination effectiveness based on antibody efficacy among the institutionalized elderly in Japan. Vaccine. 2010; 28(35): 5664–5668. doi: 10.1016/j.vaccine.2010.06.061
- Baxter R., Ray G. T., & Fireman B. H. (2010). Effect of influenza vaccination on hospitalizations in persons aged 50 years and older. Vaccine.2010; 28(45): 7267–7272. doi: 10.1016/j.vaccine.2010.08.088
- Couch R. B., Winokur P., Brady R., Belshe R., Chen W. H., Cate T. R., et al.. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine. 2007; 25(44): 7656–7663. doi: 10.1016/j.vaccine.2007.08.042
- Tosh PK, Jacobson RM, Poland GA. Influenza vaccines: from surveillance through production to protection. Mayo Clin Proc. 2010; 85(3): 257–273 doi: 10.4065/mcp.2009.0615
- Berggren A., Lazou Ahren I., Larsson N. and Onning G. Randomised, double-blind and placebo-controlled study using new probiotic lactobacilli for strengthening the body immune defence against viral infections. Eur J Nutr. 2011; 50: 203–210. doi: 10.1007/s00394-010-0127-6
- Hui S. L., Chu L. W., Peiris J. S., Chan K. H., Chu D., & Tsui W. Immune response to influenza vaccination in community-dwelling Chinese elderly persons. Vaccine. 2006; 24(25): 5371–5380. doi: 10.1016/j.vaccine.2006.04.032
Source: PubMed